GlassScriptPhysician profile
Nichelle Satterfield
NPI 1326466889
$2,596.52
in general payments reported to CMS, 2019-2025
25 companies · $423 in 2025
The $423 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $158 · 2021: $178 · 2022: $278 · 2023: $449 · 2024: $628 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $698.78 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Abbvie INC. | $336.55 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Novo Nordisk INC | $271.63 | 2021-2024 | Wegovy, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $193.36 | 2019-2025 | |
| Biogen, INC. | $166.98 | 2025 | Zurzuvae |
| Pfizer INC. | $147.72 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $94.29 | 2022-2025 | |
| Myriad Women'S Health, INC. | $91.31 | 2023 | |
| Therapeuticsmd, INC. | $91.22 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $78.70 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $69.95 | 2024-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $61.21 | 2024-2025 | Nexplanon |
| Exeltis, USA INC. | $60.34 | 2020-2025 | Slynd |
| Astellas Pharma US INC | $48.36 | 2024-2025 | Veozah |
| Lilly USA, LLC | $31.16 | 2024-2025 | Zepbound |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.42 | 2024 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $21.75 | 2024 | Endosee |
| Scynexis, INC. | $18.33 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.84 | 2019 | |
| Duchesnay USA Incorporated | $17.65 | 2019 | |
| Myovant Sciences INC. | $16.60 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.51 | 2019 | |
| Allergan, INC. | $12.31 | 2019 | |
| Lupin INC. | $11.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichelle Satterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.